2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2669

Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2001

Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2111

Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2246

Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2225

Systematic Osteoporosis Screening in Chronic Obtructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis

Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2035

Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2699

Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: L08

Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2274

Targeted Education Improves Awareness of Reproductive Health Issues Among Women with Rheumatologic Diseases

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2662

Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1990

Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2019

Tenosynovitis at the Metatarsophalangeal Joints, a Novel Feature of RA: Results from an Anatomical and Large Magnetic Resonance Imaging Study of Tendon Sheaths of the Forefoot

RA – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2174

Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2506

The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2252

The #Worldlupusday 2019 Across Twitter: An Explorative Analysis of Spreading Concepts and Sentiment Perceptions on Social Media

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].